Evidence map›Paper›PMID 40448390›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2025

Balancing Antigen Loading on Gold Nanoparticles: Implications for Future Cancer Vaccine Strategies.

Mattia Ghirardello, Ana Guerreiro, Carmen Bretón, Ismael Compañón, Julio Zabalza, Vincenzo Mangini, Jesús M Peregrina, Gonçalo J L Bernardes, Francisco Corzana

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mattia GhirardelloDepartamento de Química and Instituto de Investigación en Química de la Universidad de La Rioja (IQUR), Universidad de La Rioja, Madre de Dios, 53, Logroño, 26006, Spain.
Ana GuerreiroGIMM - Gulbenkian Institute for Molecular Medicine, Universidade de Lisboa, Avenida Professor Egas Moniz, Lisboa, 1649-028, Portugal.
Carmen BretónDepartamento de Química and Instituto de Investigación en Química de la Universidad de La Rioja (IQUR), Universidad de La Rioja, Madre de Dios, 53, Logroño, 26006, Spain.
Ismael CompañónDepartamento de Química and Instituto de Investigación en Química de la Universidad de La Rioja (IQUR), Universidad de La Rioja, Madre de Dios, 53, Logroño, 26006, Spain.
Julio ZabalzaDepartamento de Química and Instituto de Investigación en Química de la Universidad de La Rioja (IQUR), Universidad de La Rioja, Madre de Dios, 53, Logroño, 26006, Spain.
Vincenzo ManginiCenter for Biomolecular Nanotechnologies, Italian Institute of Technology, Via Barsanti, Arnesano, 73010, Italy.
Jesús M PeregrinaDepartamento de Química and Instituto de Investigación en Química de la Universidad de La Rioja (IQUR), Universidad de La Rioja, Madre de Dios, 53, Logroño, 26006, Spain.
Gonçalo J L BernardesGIMM - Gulbenkian Institute for Molecular Medicine, Universidade de Lisboa, Avenida Professor Egas Moniz, Lisboa, 1649-028, Portugal.
Francisco CorzanaDepartamento de Química and Instituto de Investigación en Química de la Universidad de La Rioja (IQUR), Universidad de La Rioja, Madre de Dios, 53, Logroño, 26006, Spain.ORCID https://orcid.org/0000-0001-5597-8127

Funding

Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa PTDC/MED-QUI/4160/2021Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa SFRH/BD/115932/2016Fundación Científica Asociación Española Contra el Cáncer INNOVA 2023Fundación Científica Asociación Española Contra el Cáncer predoctoral fellowshipHorizon 2020 Framework Programme 101034288Horizon 2020 Framework Programme 956544Spanish National Plan for Scientific and Technical Research and Innovation PDC2022-133725-C21Spanish National Plan for Scientific and Technical Research and Innovation PID2021-127622OB-I00
6 · The paper itself

Abstract

Mucin 1 (MUC1) is a promising antigen for cancer vaccine development, but its low immunogenicity poses a major challenge. In this study, we have investigated the effect of varying the surface density of an artificial MUC1 glycopeptide on gold nanoparticles by co-loading them with an ovalbumin-derived peptide. Our results show that reducing the density of the MUC1 antigen on the nanoparticles does not affect the elicited immune response, as high IgG antibody levels were observed in the immunized mice, which were comparable to those obtained with higher antigen loading. These antibodies effectively reacted with natural MUC1 expressed on breast cancer cells, promoted antibody-dependent cell-mediated cytotoxicity and specifically recognized cancer tissue in immunohistochemical assays. This work could form the basis for the development of AuNP-based multicomponent vaccines that will allow the incorporation of additional immunostimulatory or complementary antigens in the future without compromising the efficacy of the MUC1 antigen.

Indexed as

Cancer VaccinesGoldMetal NanoparticlesMucin-1AnimalsBreast NeoplasmsCell Line, TumorFemaleHumansImmunoglobulin GMiceMice, Inbred BALB COvalbuminCancer VaccinesGoldImmunoglobulin GMUC1 protein, humanMucin-1Ovalbuminbreast cancercancer vaccineglycopeptidegold nanoparticlesMUC1

Identifiers

PMID40448390
PMCPMC12238922

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.